RxDoctor Payments Data

Chantal Berez, MD

Internal Medicine · Chesterfield, MONPI 1982049623

Payments from drug & device makers

$9,333in general payments, 2019–2025

Across 558 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$869
  • Pfizer$558
  • GSK$470
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$9,315100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,333 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$103,686
Medicare patients
258
Services billed
1,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$117,440
OzempicSemaglutide73$106,171
JardianceEmpagliflozin36$50,348
TrulicityDulaglutide32$37,527
EliquisApixaban28$23,966
Tresiba Flextouch U-200Insulin Degludec20$21,836
FarxigaDapagliflozin Propanediol14$17,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,944
Tresiba Flextouch U-100Insulin Degludec21$15,917
XareltoRivaroxaban22$12,464
ArexvyRsvpref3 Antigen/As01e/Pf49$12,398
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$11,685
JanuviaSitagliptin Phosphate21$10,321
Breo ElliptaFluticasone/Vilanterol15$9,722
Incruse ElliptaUmeclidinium Bromide22$8,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,083$154,966130 claims
Novo NordiskOzempic$1,299$106,17173 claims
Boehringer IngelheimJardiance$201$50,34836 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta$470$47,190108 claims
PfizerEliquis$558$23,96628 claims
AstraZenecaFarxiga$869$17,78914 claims
Johnson & JohnsonXarelto$68$12,46422 claims
MerckJanuvia$61$10,32121 claims
AbbVieSynthroid$1,863$1,74635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →